Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CXCR4 antagonistic lipid nanoparticles loading siRNA combat refractory AML through AML1-ETO depletion and homoharringtonine sensitization.

Materials today. Bio·2026

Same author

Magneto-Mechanical Coupling Modeling and Full-Cycle Characterization of V-Shaped Crack Evolution in Q345 Steel Using Metal Magnetic Memory.

Materials (Basel, Switzerland)·2026

Same author

Change of quality of life on left-behind children in China: A follow-up study.

Medicine·2026

Same author

Active Rac1-Mediated Bone Marrow Retention Enhances CD33 CAR-T Cell Efficacy Against CD33<sup>+</sup> Leukemia Cells.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026

Same author

CXCR4-antagonistic peptide-decorated lipid nanoparticles for co- delivery of AML1-ETO siRNA to enhance chemotherapy in refractory AML.

Journal of hematology & oncology·2026

Same author

Performance difference of enrofloxacin monoclonal antibody and nanobody elicited from the same immunogen and the underlying molecular mechanism.

Food chemistry. Molecular sciences·2026

Search research articles

Related Experiment Video

Updated: Aug 25, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently.

Zhaoqi Chen^1,2,3, Yan Liu^1,2,3, Nianci Chen^1,2,3

¹State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.

Science China. Life Sciences

|October 17, 2022

Summary

This summary is machine-generated.

New bispecific CAR-T therapies targeting CD19 and CD20 show promise for treating blood cancers like lymphoma and leukemia, overcoming challenges of antigen loss and improving patient survival.

Keywords:

CD19 CD20 CLL bispecific targeting chimeric antigen receptor lymphoma

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Aug 25, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 is effective for relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
Treatment failure in chronic lymphoblastic leukemia (CLL) and non-Hodgkin's lymphoma (NHL) is often due to CD19 antigen loss and poor CAR-T cell persistence.
Targeting CD20 offers a potential salvage strategy for CD19-negative relapses.

Purpose of the Study:

To develop and evaluate novel bispecific CAR-T cell constructs targeting both CD19 and CD20 antigens.
To overcome antigen escape mechanisms and enhance CAR-T cell efficacy in B-cell malignancies.
To identify the optimal bispecific CAR structure for improved anti-leukemia and anti-lymphoma activity.

Main Methods:

Construction of tandem and loop CAR structures designed for dual targeting of CD19 and CD20.
In vitro assessment of bispecific CAR-T cell efficacy against lymphoma cell lines and primary patient cells (lymphoma, CLL).
In vivo evaluation of the most effective CAR construct in a lymphoma xenograft mouse model.

Main Results:

Bispecific CAR-T cells demonstrated dual targeting capabilities, eliminating both CD19-positive and CD19-negative tumor cells.
The loop2019 CAR construct exhibited superior efficacy at very low doses compared to other tested bispecific CAR structures.
The loop2019 CAR significantly eradicated lymphoma cell lines and primary patient cells in vitro.
Treatment with loop2019 CAR-T cells dramatically prolonged survival in a lymphoma xenograft mouse model.

Conclusions:

Bispecific CAR-T cells targeting CD19 and CD20 represent a promising strategy to overcome antigen escape in B-cell malignancies.
The loop2019 CAR structure demonstrated potent anti-tumor activity and warrants further clinical investigation.
This approach has the potential to improve treatment outcomes for patients with R/R ALL, CLL, and NHL.